biostudies-literatureUnknown28(3)Riveline JPInsulet Corporation<h4>Aims</h4>Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy.<h4>Materials and methods</h4>As part of a 13-week multicentre, parallel-group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18-70 years with T1D completed validated psychosocial questionnaires assessing health-related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ-5D-3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of lifDiabetes, obesity & metabolism2227-2236https://www.ebi.ac.uk/biostudies/studies/S-EPMC12916430biostudies-literaturePsychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.PMC12916430Suh BDowns AHami ROliver DShelton NSalhin ADong XLaffel LMKravarusic JWodetzki DIsganaitis ESiadoua MHughes MHernandez JNorlander LBloks TShoemaker RAleppo GHerrmann SHirchak CThivolet CVidal-Trecan TAverkiou XPenfornisy ACastorino KRiveline JPLewis MThorsell AHuyett LMBrown SAPenfornis AFarret AAmbler-Osborn LWalker SVienneau TRenard EMaxson ARamon VTabb CHerndon CBeatson CChristie KAkturk HKLy TTWeinstock RSGuevara ERosas KDunn ELal RADumais BJohnson JVolkening LBeltran SKipnes MSRyan TPenn SKivilaid KFimbel SVHirsch IBStumpf MAlix CBlanscet HMulvey SMandava PQamar LMiller KMVillard OChurch MMShah VNBuckingham BAGautier JFBellili DMalik FPour FMOP5‐003 Research GroupPetit CStone SLJulia JBFuller MDoolan JBode BWKingman RGoroza EAl Masri MBzdick SConroy LRReed DTurcotte CHsu LMoore AJoseph HOwnby JWilby CPotier CfalsePsychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.<h4>Aims</h4>Beyond their glycaemic benefits, automated insulin delivery (AID) systems can provide psychosocial benefits for people with type 1 diabetes (T1D) and improve quality of life. In this study, we evaluated psychosocial outcomes in adults with T1D using the tubeless Omnipod® 5 AID System compared with sensor augmented pump (SAP) therapy.<h4>Materials and methods</h4>As part of a 13-week multicentre, parallel-group, randomised controlled trial comparing intervention (tubeless AID) and control (SAP) groups (2:1), adults aged 18-70 years with T1D completed validated psychosocial questionnaires assessing health-related quality of life (European Quality of Life 5 Dimensions 3 Level Version [EQ-5D-3L] index score and visual analogue scale [VAS]), the impact of diabetes on quality of lif2026-01-01T00:00:00Z2026 Mar2026-07-16T06:40:46.696Z2026-07-09T10:41:06.335ZS-EPMC129164304150871510.1111/dom.70416